3 December 2020

Touchlight appoints Satish Muchakayala as Director of Regulatory Affairs

Touchlight announces the appointment of Satish Muchakayala to the newly created position of Director of Regulatory Affairs.

Hampton, UK – 03 December 2020

Touchlight, a biotechnology company focused on the discovery and development of DNA-based genetic medicines, today announces the appointment of Satish Muchakayala to the newly created position of Director of Regulatory Affairs. In this new role, Satish will be responsible for leading the development and implementation of the UK and global regulatory strategy for Touchlight.

Satish has over 14 years of global regulatory experience in the pharmaceutical industry, having consulted organisations of all sizes in the pre-approval regulatory phase as well as on post-approval life cycle maintenance of biopharmaceutical products. Prior to joining Touchlight, Satish worked in various regulatory positions at UCB, Johnson and Johnson, and GSK. He has a Master’s degree in Pharmaceutical Sciences and is one of the consultant editors for TOPRA Regulatory Rapporteur.

“We are delighted to have Satish join Touchlight in this exciting period, when nucleic acid vaccines are in the spotlight,” said Jonny Ohlson, Executive Chairman of Touchlight. “Satish is an accomplished regulatory affairs executive with in-depth experience in regulatory affairs in all phases of pharmaceutical research and development, at a global level. We look forward to Satish supporting us in progress approvals for Touchlight’s pipeline.”

Commenting on his appointment, Satish Muchakayala said: “With a Covid-19 nucleic acid vaccine now approved, efficient large scale manufacturing of these vaccines will be crucial. Touchlight’s dbDNA technology has the ability to accelerate manufacturing without compromising on safety or efficacy. Regulatory affairs will now be key, and I am excited to join Touchlight at such an important time for the company’s growth.”

- ENDS -

About Touchlight

Touchlight is a privately-owned CDMO based in London, U.K., focused on the provision of DNA services and manufacture of enzymatically produced doggybone DNA (dbDNA™) to enable the development of genetic medicines. Touchlight provide rapid, enzymatic DNA development and manufacturing for all advanced therapy production, including mRNA, viral and non-viral gene therapy and DNA API. dbDNA is a minimal, linear, covalently closed structure, which eliminates bacterial sequences. Touchlight’s revolutionary enzymatic production platform enables unprecedented speed, scale, and the ability to target genes with a size and complexity that is impossible with current technologies. Clients can be supported from pre-clinical through development and supply, to licencing and tech transfer for use in-house.

Issued for and on behalf of Touchlight by Instinctif Partners.

For more information please contact:

Karen Fallen, Chief Executive Officer Instinctif
Robin Bodicoat, Head of Marketing E: touchlight@instinctif.com
E: info@touchlight.com T: +44 20 7457 2020
T: +44 20 8481 9200